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Abstract: 
Purple acid phosphatases (PAPs) are metalloenzymes that catalyse the hydrolysis of 
phosphate esters under acidic conditions. Their active site contains a Fe(III)Fe(II) metal centre 
in mammals and a Fe(III)Zn(II) or Fe(III)Mn(II) metal centre in plants. In humans, elevated 
PAP levels in serum strongly correlate with the progression of osteoporosis and metabolic 
bone malignancies, which make PAP a target suitable for the development of 
chemotherapeutics to combat bone ailments. Due to difficulties in obtaining the human 
enzyme, the corresponding enzymes from red kidney bean and pig have been used previously 
to develop specific PAP inhibitors. Here, existing lead compounds were further elaborated to 
create a series of inhibitors with Ki values as low as ~30 µM. The inhibition constants of these 
compounds were of comparable magnitude for pig and red kidney bean PAPs, indicating that 
relevant binding interactions are conserved. The crystal structure of red kidney bean PAP in 
complex with the most potent inhibitor in this series, compound 4f, was solved to 2.40 Å 
resolution.  This inhibitor coordinates directly to the binuclear metal centre in the active site 
as expected based on its competitive mode of inhibition. Docking simulations predict that this 
compound binds to human PAP in a similar mode. This study presents the first example of a 
PAP structure in complex with an inhibitor that is of relevance to the development of anti-
osteoporotic chemotherapeutics. 
 
1. Introduction 
Purple acid phosphatases (PAPs, also referred to as tartrate-resistant acid phosphatases) are 
metalloenzymes found in animals, plants and fungi [1-5]. They utilise a binuclear metal centre 
to catalyse the hydrolysis of phosphate esters and anhydrides under acidic conditions, with an 
optimal pH ~5 [6-12]. The overall reaction is given in Equation 1. 
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PAPs are non-specific enzymes that can dephosphorylate diverse substrates, including ATP, 
ADP and para-nitrophenyl phosphate (pNPP) [1-4, 13], as well as phosphoproteins such as 
osteopontin and bone sialoprotein [14-15]. Several roles for mammalian PAPs have been 
suggested. Pig PAP found in the allantoic fluid of pregnant sows is believed to transport iron 
from the mother to the foetus during gestation [16], and therefore the enzyme is also referred 
to as uteroferrin [6, 17-19]. In humans, PAP function appears to be tissue-specific; the 
enzyme is involved in the inflammatory response of antigen-presenting cells [20], as well as 
in bone resorptive processes in osteoclasts [15, 21]. The diverse roles of mammalian PAP are 
associated with the enzyme’s bifunctional character; apart from its hydrolytic activity it can 
also act as a Fenton catalyst due to the presence of its redox active Fe(III)Fe(II/III) centre 
[22]. It has been hypothesised that the reactive oxygen species (ROS)-generating activity of 
PAP could play a role in collagen degradation [23]. Although the substrate(s) of PAP in bone 
tissue is unknown, studies with transgenic mice clearly established the enzyme’s function in 
bone turnover. Mice overexpressing the PAP gene are found to be osteoporotic [14] and show 
an increase in bone turnover [24]. In contrast, mice deficient in PAP display a phenotype 
characteristic of osteopetrosis [24], with increased bone mineral density, abnormal 
ossification [14] and defects in the resorption and mineralisation of growing bone [25]. Thus, 
PAP has emerged as a target for inhibitors that may lead to the development of novel 
treatments for osteoporosis, bone malignancies and metabolic bone diseases.  
In the absence of effective recombinant expression systems for human PAP the enzymes 
extracted from pig uterine fluid (i.e. uteroferrin) and red kidney bean PAP (rkbPAP) have 
been used as models to test the efficacy of inhibitors. Despite the modest sequence similarity 
between rkbPAP and mammalian PAPs [26-27] its inclusion into an inhibitor design program 
is warranted on the basis of similar (i) substrate specificities, (ii) interactions with known 
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inhibitors and (iii) mechanism [19, 28-29]. A number of thiol and phosphonate compounds 
with IC50 values 80–3000 µM have been developed [30]; similar IC50 values were reported for 
a series of phosphotyrosine-containing tripeptides [28]. Our group reported a series of α-
alkoxynaphthylmethylphosphonic acids [31], acyl derivatives of α-aminonaphthylmethyl 
phosphonic acid [32] and acyl derivatives of 6-aminopenicillanic acid [33] as inhibitors of 
PAP with Ki and IC50 values in the low micromolar range. We also employed a fragment-
based screening approach to identify three potential inhibitor leads; crystal structures 
provided insight about the mode of their binding in the active site of rkbPAP [27]. Here, we 
used these fragments as starting points for the design of a new series of inhibitors with 
improved binding interactions. 
 
2. Results and Discussion 
Inhibitor synthesis: In a previous study, four fragments from a MaybridgeTM library were 
identified as promising inhibitor leads for PAPs [27]. The molecular structures of these 
compounds (i.e. 1, 2, 3 and 4a) are shown in Figure 1. The crystal structures of rkbPAP in 
complex with compounds 2 and 4a (competitive inhibitors with Ki values of 43 µM and 340 
µM for rkbPAP and 59 µM and 42 µM pig PAP, respectively [27]) demonstrate that the active 
site of the enzyme offers numerous structural features to allow further elaboration of inhibitor 
molecules with high affinity and specificity (Figure 1). 
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Figure 1: (a) Four fragments identified from a MaybridgeTM compound library as PAP inhibitors. (b) Crystal 
structure of rkbPAP (yellow surface) in complex with compound 4a (as sticks with cyan carbons), and (c) in 
complex with 2.Water molecules are shown as red spheres [27]. 
Using compounds 2 and 4a as starting points, we generated two series of derivatives (i.e. 7a-b 
and 4b-h, respectively). To synthesise the two monocyclic alkoxy benzyl ether derivatives 
(7a-b)  of compound 2 (i.e. the benzofuran) the 2-alkoxy benzaldehydes (6a-b) were first 
prepared by alkylation of salicylaldehyde (5) using alkyl halides and potassium carbonate in 
DMF solution, followed by sodium borohydride reduction to the corresponding benzyl 
alcohols [34] (Scheme 1). 
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Scheme 1. Reagents and Conditions: (a) RX, K2CO3, DMF, r.t., 36 h. 6a (86%), 6b (84%); (b) NaBH4, 
2 M, NaOH, MeOH, r.t., 4 h. 7a (74%); 7b (85%). 
 
The preparation of compounds 4a-f first required the synthesis of the intermediates 11a-f, as 
outlined in Scheme 2. Following the method described by Gududuru et al. [35], the 
hydrochloride salt of the methyl ester of L-cysteine (9), which was first prepared by refluxing 
L-cysteine (8) with SOCl2 in methanol, was reacted with a series of aromatic aldehydes 10a-f 
to give the corresponding thiazolidine methyl ester intermediates 11a-f.  
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Scheme 2. Reagents and Conditions: (a) SOCl2, MeOH, ∆, 3 h, 100%; (b) 9, NaHCO3, EtOH, H2O, 
r.t., 14 h. 11a (65%); 11b (74%); 11c (81%); 11d (57%); 11e (79%); 11f (37%); (c) N-
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bromosuccinimide, benzoyl peroxide, CCl4, ∆, 14 h. 12a (23%), 12b (26%), 12c (17%), 12d (19%), 
12e (32%), 12f (16%); (d) 2 M NaOH, MeOH, 0 ºC, 2 h. 4a (98%), 4b (80%), 4c (84%), 4d (100%), 
4e (100%), 4f (100%). 
 
The thiazole carboxylic acid derivatives 4a-f were prepared in two steps from their 
corresponding thiazolidine intermediates 11a-f, by oxidation of 11a-f using N-
bromosuccinimide (NBS) and benzoyl peroxide, followed by basic hydrolysis of the methyl 
esters 12a-f, using the method described by Gududuru et al. [35] (Scheme 2). 
The syntheses of the thiazole dicarboxylic acids 4g-h are outlined in Scheme 3. Following the 
method described by Ashram [36], the two aromatic aldehydes 13 and 15 were prepared by 
refluxing the 2-hydroxy aromatic aldehydes 5 and 14, respectively, with ethyl 2-bromoacetate 
in the presence of potassium carbonate in acetone. The two aromatic aldehydes, 13 and 15, 
then reacted with compound 9 to give the corresponding thiazolidine derivatives 11g-h in 
12% and 77% yields, respectively. Oxidation of 11g-h to the thiazoles 12g-h, followed by 
saponification, gave the carboxylic acids 4g-h [35] (Scheme 3). 
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Scheme 3. Reagents and Conditions: (a) BrCH2CO2Et, K2CO3, Me2CO, ∆, 4 h. 13 (86%), 15 (48%); 
(b) 9, NaHCO3, EtOH, H2O, r.t., 14 h. 11g (12%), 11h (77%); (c) N-bromosuccinimide, benzoyl 
peroxide, CCl4, ∆, 14 h. 12g (17%), 12h (8%); (d) 2 M NaOH, MeOH, r.t., 4 h. 4g (73%), 4h (80%).  
 
Additionally, a series of thiazolidine-4-carboxylic acid derivatives 16a-c and 16f-j were 
synthesised for testing against both rkb and pig PAP enzymes to investigate the importance of 
the unsaturation of the thiazole ring for the activity of the compounds. Treating L-cysteine (8) 
with a number of aromatic aldehydes 10a-c and 10f-j in ethanol solution gave the 
corresponding thiazolidine-4-carboxylic acid derivatives 16a-c and 16f-j, as mixtures of cis 
and trans isomers, in good yields [35] (Scheme 4). 
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f, Ar = naphth-1-yl
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h, Ar = 4-hydroxyphenyl
i, Ar = 2-hydroxyphenyl
j, Ar = 2-furyl
 
Scheme 4. Reagents and Conditions: (a) L-Cysteine (8), EtOH, r.t., 5 h. 16a (63%), 16b (66%), 16c 
(52%), 16f (68%), 16g (70%), 16h (64%), 16i (93%), 16j (66%). 
 
Inhibition assays: The inhibitory effects of compounds 7a-b and 4a-h were tested using a 
standard kinetic assay with the chromophoric substrate para-nitrophenyl phosphate (pNPP); 
both rkbPAP and fully reduced pig PAP were used. In the first round of assessment, 
percentage inhibition was measured at a fixed concentration (i.e. 100 µM) of inhibitor. This 
initial screen indicated that compound 4f was the most promising lead; both pig PAP and 
rkbPAP activities were reduced to approximately half the value measured in its absence. 
Since accurate measurement of the binding affinity of a possible inhibitor also depends on its 
mode of binding and its competition with a substrate of the reaction, several of the above 
compounds were tested in inhibition assays where the concentrations of both the substrate and 
inhibitors were varied. Relevant parameters are summarised in Table 1. Kic and Kiuc represent 
the inhibitor dissociation constants for the enzyme-inhibitor and enzyme-substrate-inhibitor 
complex, respectively (i.e. competitive vs uncompetitive inhibition constants). Compounds 
7a-b and 4g-h exhibited little or no inhibitory activity against either pig or rkbPAP 
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Table 1: Kinetic data for inhibitors 4a-f against fully reduced pig PAP and rkbPAP at pH 4.9.  
Compound Enzyme Kic (µM) Kiuc (µM) 
4a Pig PAP 42 ± 14 - 
4a rkbPAP 340 ± 130 - 
4b Pig PAP 190 ± 62 - 
4b rkbPAP - - 
4c Pig PAP 120 ± 35 - 
4c rkbPAP 400 ± 210 770 ± 700 
4d Pig PAP 49 ± 13 - 
4d rkbPAP 530 ± 480 - 
4e Pig PAP 630 ± 570 350 ± 180 
4e rkbPAP 920 ± 630 - 
4f Pig PAP 33 ± 15 110 ± 69 
4f rkbPAP 185 ± 75 - 
 
For each of the compounds 4a – 4f their inhibitory effects on pig PAP and rkbPAP are within 
the same order of magnitude, but in each case the binding is stronger for the pig enzyme, and 
in most cases the mode of inhibition is competitive.  The exceptions are compounds 4e and 4f 
that also have a contribution from an uncompetitive binding mode (characterised by Kiuc) in 
pig PAP.  However, overall only compound 4f has a binding affinity (based on the magnitude 
of respective Ki values) that is modestly better than that of the parental compound 4a (Table 
1). 
The thiazolidine-4-carboxylic acid derivatives 16a-c and 16f-j were tested against a fully 
reduced pig PAP enzyme at 100 µM concentrations using 5 mM pNPP as a substrate. This 
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series of compounds did not show any inhibition effect, except for compound 16k, that 
displays modest (~40%) inhibition.  Consequently, this series of compounds was not further 
investigated. 
 
Crystallographic investigations of inhibitor binding 
Crystallographic investigations into the binding mode of compound 4f in complex with rkbPAP 
were undertaken wherein a rkbPAP crystal was grown and then soaked with a solution containing 
4f. The crystal diffracted to 2.4 Å resolution (Table 2) and has the same space group as described 
previously [27], and with the asymmetric unit consisting of two dimers of rkbPAP; the monomers 
are denoted A through D. After fitting of the polypeptide, amino acid side chains, metal ions and 
solvent molecules, 4f was modelled into the difference electron densities of Polder omit maps. 
Polder maps were chosen for this study since they are optimal for visualisation of weak binding 
inhibitors obscured by bulk solvent scaling [37]. Compound 4f was modelled in subunit A (> 
4.75 σ) and subunit B (> 5.24 σ) (Figure 2A,B). In subunits C and D, the difference electron 
densities indicate the presence of a sulfate anion bound to the metal centre.  
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Figure 2: (A) Polder (Fo-Fc) omit electron density map (> 5.24 σ) and cartoon/stick representation showing the fit 
of the inhibitor 4f (magenta carbons) to the difference electron density in subunit B of rkbPAP (light blue carbons), 
the metals are shown as green spheres (B) Surface and stick representation of the active site of rkbPAP (turquoise 
surface) in complex with 4f (CPK colouring sticks and blue surface), metals are shown as black spheres. For clarity 
of presentation, this view is rotated by 180º relative to 2(A). (C) Surface and stick representation showing the result 
of MVD predicting the binding mode of 4f (green sticks) to rkbPAP superimposed onto the crystal structure of 
rkbPAP (turquoise surface) in complex with 4f (yellow sticks); the metals are shown as black spheres (D) Surface 
and stick representation showing the result of MVD predicting the binding mode of 4f (CPK colouring sticks, blue 
surface) to human PAP (purple surface); the metals are shown as black spheres. 
 
The inhibitor binds through its carboxylate group in a µ-1,3 bidentate mode to the metal ions in 
the active site, more closely to Fe(III) (1.7 Å) than to Zn(II) (2.2 Å) (Figure 2A). The sulfur atom 
in the thiazole ring of the inhibitor forms a hydrogen bond with the hydroxyl group of the 
adjacent Y365 side chain (3.2 Å). The nitrogen atom in the thiazole ring forms a hydrogen bond 
(3.0 Å) with a nitrogen atom in the imidazole group of H296, and the thiazole ring forms π-cation 
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interactions with H295 and H296 (3.0-4.0 Å). The naphthalene ring, while not as well resolved as 
the thiazole ring (likely to be due to some structural flexibility), forms π-cation interactions with 
the guanidino group of R258 from the adjacent subunit in the rkbPAP dimer (3.3-4.0 Å) and with 
the imidazole group of H295 (2.90-3.70 Å).  In comparison to the binding interactions of 
compound 4a (Figure 3) both the carboxylate and thiazole moieties are positioned similarly in the 
two molecules, suggesting that the naphthalene ring in 4f enhances inhibitor binding despite not 
being locked in place by non-covalent associations. This indicates further improvements are 
possible to improve potency. 
 
Figure 3:  Stereo superimposition of the crystal structure of rkbPAP with 4a bound to the active site of subunit B 
(PDB ID: 4DHL, yellow carbons) and rkbPAP with 4f bound to the active site of subunit B (cyan carbons) to the 
active site. Substitution of the p-tolyl group with a p-naphthyl group picks up an additional interaction with H295. 
 
Table 2: Data collection and refinement statistics for the rkbPAP-4f complex 
 
 
 
Data collection    
Temperature 100  
Resolution range (Å) 43.26 - 2.40 (2.49 - 2.40)a  
Total number of reflections 467895 (30571)  
Total number unique 107272 (10656)  
Completeness (%) 99.4 (97.5)  
^Rmerge 0.083 (0.280)  
Mean I/σI 
CC(1/2) 
10.9 (3.4) 
0.98 (0.93) 
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Mosaicity (°) 0.27  
Unit cell lengths (Å) a  = b = 126.21 c  = 297.12  
Space group P 31 2 1   
 
Refinement  
 
 
Total number of atoms 15,764  
Number of water molecules 1,225  
Wilson B-factor (Å2) 33.66  
*Rwork  0.172  
#Rfree  
RMS bonds  (Å) 
0.223 
0.009 
 
RMS angles (°) 
 
0.957 
 
 
Ramachandran statistics (%)   
Favoured  95.02  
Allowed  4.04  
Outlier 0.94 
 
 
*Rwork = Σ|Fo|-|Fc|/Σ|Fo| and is calculated using 95% of the total reflections, and 
#Rfree uses the remaining 5% of the reflections. ^Rmerge = ΣhklΣi|Ii(hkl)-
I(hkl)|/ΣhklΣi Ii(hkl). aValues in parentheses are for the highest resolution shell. 
 
The occupancy and B-factors of the inhibitor and the neighbouring residues have been refined. 
The occupancy is close to 0.9 (0.84 on average) for the inhibitor and the B-factors for the 
inhibitor are, on average, approximately double that of the neighbouring residues (data not 
shown). This suggests that the inhibitor is stabilised in the active site but not necessarily bound 
with high affinity. The Ki value of 185 ± 75 for this compound with rkb PAP supports this. 
 
Docking studies 
Active site comparison of human, pig and red kidney bean PAPs 
To further validate the use of red kidney bean PAP and pig PAP as model systems for human 
PAP, we carried out a three dimensional structure-based alignment. It shows that the position of 
the metal ions and the three-dimensional arrangement of the metal-coordinating residues are 
completely conserved across the three species and that the amino acids that form the surface of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
the active site share 100% sequence identity between the human and pig enzymes (Figure 4). 
This makes pig PAP an ideal model for human PAP inhibitor design. 
 
Figure 4: (A) Superimposition of the structure of pig PAP with two conformations of phosphate bound (PDB ID: 
5UQ6, cyan) and recombinant human PAP with bound phosphate (PDB ID: 1WAR, yellow). All active site residues 
are fully conserved. (B) Structure-based alignment of the active sites of pig PAP (PDB ID: 5UQ6, cyan) and rkbPAP 
(PDB ID: 4KBP, magenta) with phosphate omitted, highlighting that most residues surrounding the active site are 
conserved or semi-conserved between the two enzymes. M is either Fe(II/III) in pig and human PAPs or Zn(II) in 
rkbPAP. Pi represents inorganic phosphate. 
 
Docking studies were undertaken to predict the binding mode of 4f to human PAP (Figure 2C-D). 
Firstly, the accuracy of the docking algorithm was gauged by verifying its ability to predict the 
correct binding mode of 4f to rkbPAP. As seen previously [27], the MolDock Simplex Evolution 
(SE) algorithm can predict the correct binding mode of an inhibitor to rkbPAP with reasonable 
accuracy (Figure 2C). The same algorithm was used to dock 4f to human PAP (Figure 2D). In the 
optimal conformation the carboxylate group of the inhibitor coordinates bidentately to the two 
metals in the active site as observed in the crystal structure of the rkbPAP-4f complex (Figure 
2A). The thiazole ring of the inhibitor forms hydrophobic interactions with the side-chain of 
conserved N89 (N201 in rkbPAP). The thiazole sulfur is oriented towards a groove in the 
interface between the conserved metal ligating residues N89 and H221 (N201 and H325 in 
rkbPAP) and the mammalian repression loop (N142, S143 and D144, spatially equivalent Y365 
A                                                                         B
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in rkbPAP), whereby it is stabilised by van der Waals interactions with the side-chains of these 
residues and by a hydrogen bond with the side chain amino group of Q149. The remainder of the 
thiazole ring is stabilised by π-cation interactions with H90 and H193 (H202 and H296 in 
rkbPAP, respectively). The naphthalene ring fits into a hydrophobic wedge formed by the 
sidechains of F54 and F242. Pose binding energies obtained from Molegro Virtual Docker 
(MVD) algorithm are -89.51 kcal/mol and -56.61 kcal/mol for the interactions of 4f with human 
PAP and rkbPAP, respectively, which suggests that this inhibitor binds tighter to the human 
enzyme, in good agreement with the enhanced affinity of 4f for pig PAP when compared to 
rkbPAP (Table 1). The major contribution to the enhanced affinity of 4f to the human enzyme is 
due to a stronger interaction of the naphthalene ring with the hydrophobic side chains of F54 and 
F242 when compared to R258 in rkbPAP; however, the thiazole portion of the inhibitor also 
contributes to the difference due to its interaction with the repression loop that is characteristic 
for mammalian PAPs.  
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3. Conclusion 
The role of PAPs in bone resorption has been well established since studies of transgenic 
mice demonstrated that abnormal expression levels of this enzyme are associated with bone 
disorders; overexpression of PAP leads to an osteoporotic phenotype, while a knockout 
displays features characteristic of osteopetrosis [15]. While these observations make PAP a 
target for the development of chemotherapeutics to combat osteoporosis, little effort has been 
directed towards the design of specific and potent inhibitors of this enzyme. Though a recent 
paper used a small molecule screening library to identify a family of carboxamides as low 
micromolar inhibitors of human PAP [5],  the majority of inhibitors discovered to date are 
simple anions (e.g. phosphate, vanadate or sulfate [1-4, 8-9, 19, 29] that target the bimetallic 
metal centre. Since the bimetallic metal centre and its seven amino acid ligands are well 
conserved amongst a range of metallohydrolases (as an example, enzymes such as the 
diesterases GpdQ and Rv0805 have an active site that is nearly identical to that of PAPs [38-
39] it is not surprising that inhibitors targeting mainly the metal centre are non-specific. More 
complex molecules that may exploit structural features in the outer sphere of the PAP active 
site were developed but their precise binding modes had not been explored, largely due to the 
lack of crystallographic data.  In this respect, the crystal structures of several small fragments 
in complex with rkbPAP provided, for the first time, detailed insight into how potential 
inhibitor leads may interact with a PAP [27].  Here, two of these fragments (2 and 4a in 
Figure 1a) were used as starting points for further elaboration.  Of significance is that our 
structure activity relationship (SAR) results indicate that most of the thiazolidine derivatives 
of 16 are ineffective inhibitors of PAPs.  The exception is compound 16k, bearing a 
naphthalene ring. Upon oxidising its thiazolidine ring to the corresponding thiazole while 
retaining the naphthalene ring leads to compound 4f. This compound displays improved 
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binding affinity, and its structure in complex with rkbPAP guides further modifications to 
enhance the binding specificity and potency (Figure 2).   
To date it has not been possible to obtain crystal structures of catalytically active forms of a 
mammalian PAP. Available structures contain an inactive di-Fe(III) centre, mostly in 
complex with phosphate [40-41].  In contrast, plant PAPs crystallise readily in their 
catalytically active form, largely due to the fact that they contain redox-inactive Fe(III)Zn(II) 
or Fe(III)Mn(II) centres [8-11, 13, 42-43].  Consequently, in particular rkbPAP has been 
employed as a model to investigate the effect of inhibitors on PAPs.  The observation of 
reasonably conserved (i) catalytic properties, including substrate specificities, mechanism and 
inhibition by non-specific inhibitors, and (ii) amino acid side chains in the vicinity of the 
active site validate the selection of rkbPAP as a model for mammalian PAPs [1-4].  Indeed, 
all compounds tested here have comparable inhibitory effects for pig PAP and rkbPAP, albeit 
their binding to the mammalian enzyme is always more potent (Table 1).  In order to gain 
insight into how 4f binds to the human enzyme in silico docking was employed.  The 
methodology was initially tested using rkbPAP to demonstrate that the predicted (in silico) 
mode of binding of 4f is virtually identical to that observed experimentally (in the crystal 
structure; Figure 2).  Indeed, the inhibitor is predicted to bind better to the mammalian 
enzyme, in part due to additional interactions between this compound and the repression loop 
that is characteristic for mammalian PAPs [40].  This predicted improvement in binding is 
reflected in the lower Ki of pig PAP for 4f when compared to rkbPAP (Table 1). 
In summary, this study provides the first crystallographic insight into a rationally designed 
inhibitor for PAP.  The structure provides guidance for the further elaboration of PAP 
inhibitors that may find applications in the treatment of conditions associated with elevated 
levels of this enzyme, including not only osteoporosis but potentially also AIDS 
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encephalopathy [44], Gaucher’s disease [45], hairy cell leukemia [46], Alzheimer’s disease 
[47] and bone metastases [48-49].  
 
4. Experimental  
4.1. Enzyme preparation and Purification 
Purple acid phosphatase from red kidney bean (rkbPAP) was purified following a previously 
published protocol [50]. Briefly, red kidney beans (Phaseolus vulgaris) were ground in a 
Waring blender and suspended in 0.5 M sodium chloride. The suspension was filtered through 
a muslin cloth, followed by ethanol fractionation and ammonium sulfate precipitation and 
further purified by ion-exchange chromatography using a CM-cellulose column followed by 
gel filtration on a Sephadex S-300 column. The resulting preparation was concentrated to 23.8 
mg⁄mL using a Millipore Amicon centrifugal concentrator and stored at 4 ºC in 0.5 M sodium 
chloride. Pig PAP was extracted from the uterine fluid of a pregnant sow and purified by ion-
exchange chromatography using CM-cellulose followed by gel filtration on a Sephadex G-75 
[51]. Purified pig PAP was concentrated to 8.1 mg⁄mL and stored at 20 oC in 100 mM acetate 
buffer at pH 4.9. Protein concentrations were determined by measuring the absorbance at 280 
nm using extinction coefficients of 1.41 for a 1 mg⁄mL solution (28.6 µM) of pig PAP and 2.1 
for a 1 mg⁄mL solution (9.1 µM) of rkbPAP. SDS-PAGE analysis showed that the enzymes 
were >95% pure. 
4.2. Crystallisation, soaking and cryoprotection 
Crystallisation of rkbPAP was achieved using previously determined conditions [42]. Once 
crystals had reached a size of ~0.1 mm in all three dimensions, an equivalent volume of 
cryoprotectant containing the inhibitor was added to the hanging drop. This solution consisted 
of 0.1 M sodium citrate pH 5.0, 0.1 M lithium chloride, 25% polyethylene glycol 3350, 20% 
isopropyl alcohol, 10% glycerol and 4 mM of 4f. This was introduced 4 days before the data 
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collection. For cryoprotection, a crystal from the above preparation was soaked in 
cryoprotectant (containing the inhibitor) for 10 s before placing it in the cryostream (100 K). 
4.3. Data collection & analysis 
Data were collected using a FR-E X-ray generator (voltage: 45 kV, current: 45 mA) and 
recorded using a Raxis IV++ imaging plate at UQ. CuKα X-rays (wavelength: 1.54 Å) were 
used for these diffraction studies. The program Rigaku Crystal clear 2.0 [52] was used to 
integrate and scale reflections and Scala in CCP4 was used to scale and merge the data [53]. 
Initial protein model for refinements was that of the crystal structure of rkbPAP in complex 
with 4a (PDB access code: 4DHL) with the inhibitor removed from the active site. 
Refinements and building of Polder maps were performed using PHENIX [54] and model 
building was undertaken using Coot [55]. Figure 2A was produced using CCP4MG [56] and 
Figures 2B-D were produced using MVD [57]. Coordinates and structure factors for the 
complex have been deposited in the Protein Data Bank with access code 6G46.  
4.4. Computational docking studies 
Docking studies were undertaken with MVD [57] using the MolDock SE algorithm with 
flexible residues using Tabu clustering and softened potentials. The ligand search space was 
confined to a 9 Å sphere originating from the metal centre of PAP. For rkbPAP, the receptor 
coordinates used were those of the crystal structure of the enzyme in complex with the 
inhibitor obtained here. For human PAP, the coordinates used were those of recombinant 
human PAP in complex with phosphate (PDB code 1WAR) [40] with the phosphate anion 
omitted from the active site. Water molecules were removed from all coordinate files prior to 
docking. 
4.5. Enzyme kinetics 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
Inhibition assays with both pig PAP and rkbPAP were performed in 96 well 400 µL multi-
titre plates using a UV/Vis multiplate spectrophotometer [29]. Prior to its use in kinetic assays 
pPAP was fully reduced to the heterovalent Fe(III)Fe(II) state to ascertain maximum activity 
by incubating it with 0.77 mM β-mercaptoethanol for ten minutes at 37 oC. Kinetic 
measurements were carried out at pH 4.9 (0.1 M acetate buffer in 25% DMSO) at 25 oC using 
para-nitrophenyl phosphate (pNPP) as substrate at different concentrations (1, 3, 5, 7.5, 10 
and 12.5 mM). The rate of product (p-nitrophenol) formation was measured at λ = 405 nm (ε 
= 343 M-1cm-1) [13]. Enzyme concentration used was 12 nM, while the concentrations for 
tested compounds ranged from 50 µM to 300 µM. The data were analysed by non-linear 
regression using the general inhibition equation (equation 2) and the program WinCurveFit 
(Kevin Raner software). 
 
Equation 2 
In this equation, Kic and Kiuc represent the equilibrium dissociation constants for competitive 
and uncompetitive inhibitor binding, respectively, while Vmax, KM, [S] and [I] represent the 
maximum rate of product formation, the Michaelis constant, substrate concentration and 
inhibitor concentration, respectively. 
4.6. Experimental chemistry 
Light petroleum (LP, b.p. 40-60 °C) was distilled before use. Flash chromatography was 
carried out with Merck Kieselgel 60 as described by Still [58]. NMR experiments were 
recorded on 300, 400 and 500 MHz spectrometers (Bruker, Rheinstetten, Germany). 
Chemical shifts are reported in parts per million (ppm) on a δ scale, relative to the solvent 
peak (CDCl3 δH 7.24, δC 77.0; (CD3)2SO δH 2.49, δC 39.5; MeOD δH 3.30, δC 49.0). Coupling 
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constants (J) are reported in hertz and peak multiplicities described as singlet (s), doublet (d), 
triplet (t), quartet (q), septet (sept), multiplet (m), or broad (br). High resolution electrospray 
ionisation accurate mass measurements were recorded in positive and negative mode on a 
quadrupole – time of flight instrument (Bruker) with an ESI source. Accurate mass 
measurements were carried out with external calibration using sodium formate as reference 
calibrant and/or Agilent tune mix (mw > 500). Low and high resolution electron impact 
ionisation mass measurements were recorded using perfluorokerosene-H as reference 
calibrant. For TLC staining, Ce(SO4)2 and/or KMnO4 were used. Ce(SO4)2 dye ingredients: 
2.5 g phosphomolybdic acid; 1 g ceric sulfate; 100 mL water and 8 mL concentrated sulfuric 
acid. KMnO4 dye ingredients: 3 g potassium permanganate; 20 g potassium carbonate; 5 mL 
5% sodium hydroxide and 300 mL water.   
4.6.1. General method for preparation of 2-alkoxy benzaldehydes (6a-b) [59] 
 
Salicylaldehyde (5) (3.66 g, 3.2 mL, 30 mmol) was added to a suspension of potassium 
carbonate (8.29 g, 60 mmol) in DMF (50 mL). Alkyl halide was then added dropwise and the 
solution was stirred for 36 h under an atmosphere of argon. Water (150 mL) was added and 
the mixture was extracted with diethyl ether (3 x 50 mL). The combined organic layers were 
washed with 2M NaOH (3 x 50 mL), dried over Na2SO4, filtered and evaporated in vacuo to 
afford the 2-alkoxy benzaldehyde 6a-b. 
4.6.1.1. 2-Ethoxybenzaldehyde (6a) [59] 
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The alkyl halide used was ethyl iodide (1 eq, 4.68 g, 2.4 mL, 30 mmol), which afforded 6a as 
a yellow oil (3.85 g, 86%). Rf : 0.51 (10% EtOAc in LP, UV and KMnO4 dip). 1H NMR (300 
MHz, CDCl3) δ 1.38 (3H, t, J 7.0 Hz), 4.06 (2H, q, J 7.0 Hz), 6.87 – 6.93 (2H, m), 7.43 – 7.47 
(1H, m), 7.71 (1H, dd, J 1.8 Hz, J 7.5 Hz), 10.41 (1H, s); 13C NMR (75 MHz, CDCl3) δ 14.4, 
64.0, 112.4, 120.3, 124.6, 128.0, 135.8, 161.2, 189.8. NMR spectra are in agreement with 
those reported by Leardini [59]. 
 
4.6.1.2. 2-Isopropoxybenzaldehyde (6b) [59] 
 
The alkyl halide used was isopropyl bromide (1.1 eq, 4.06 g, 3.1 mL, 33 mmol), which 
afforded 6b as a yellow oil (4.1 g, 84%). Rf : 0.59 (10% EtOAc in LP, UV and KMnO4 dip). 
1H NMR (400 MHz, CDCl3) δ 1.34 (6H, d, J 6.0 Hz), 4.62 (1H, sept, J 6.0 Hz), 6.90 – 6.95 
(2H, m), 7.43 – 7.48 (1H, m), 7.77 (1H, dd, J 1.9 Hz, J 7.6 Hz), 10.45 (1H, s); 13C NMR (100 
MHz, CDCl3) δ 21.8, 70.9, 113.9, 120.2, 125.6, 128.1, 135.6, 160.5, 190.0. NMR spectra are 
in agreement with those reported by Leardini [59]. 
4.6.2. General method for preparation of 2-alkoxy benzyl alcohols (7a-b)  
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These compounds 7a-b were prepared using the general method described by Zartler and 
Sharpiro [34]. A solution of sodium borohydride (0.37 eq, 28 mg, 0.74 mmol) in 2M NaOH 
(40 µL) diluted with water (360 µL) was added dropwise to a solution of the 2-alkoxy 
benzaldehyde (6a-b) (2 mmol) in methanol (2 mL) at 18 – 25 oC. The reaction mixture was 
stirred for 4 h at room temperature and then evaporated in vacuo. Methanol (2 x 10 mL) was 
added and evaporated in vacuo. HCl (5%, 10 mL) was added to the residue which was 
extracted with diethyl ether (2 x 20 mL). The combined organic layers were dried over 
Na2SO4, filtered and evaporated in vacuo to afford 7a-b. 
4.6.2.1. 2-Ethoxybenzyl alcohol (7a) 
 
The crude product was purified by silica flash column chromatography (10% EtOAc in LP) to 
afford 7a as a colourless oil (224 mg, 74%) Rf : 0.28 (10% EtOAc in LP, UV and KMnO4 
dip). 1H NMR (300 MHz, CDCl3) δ 1.41 (3H, t, J 7.0 Hz), 3.18 (1H, s, OH), 4.02 (2H, q, J 
7.0 Hz),  4.68 (2H, s), 6.83 (1H, d, J 8.2 Hz ), 6.92 (1H, dt, J 0.8 Hz, J 7.4 Hz), 7.21 – 7.32 
(2H, m); 13C NMR (75 MHz, CDCl3) δ 14.5, 61.0, 63.2, 110.7, 120.1, 128.0, 128.2, 129.1, 
156.2. NMR spectra are in agreement with those reported by Wang [60]. 
4.6.2.2. 2-Isopropoxybenzyl alcohol (7b) 
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Colorless oil (282 mg, 85%) Rf : 0.43 (10% EtOAc in LP, UV and KMnO4 dip). 1H NMR 
(500 MHz, CDCl3) δ 1.36 (6H, d, J 6.1 Hz), 2.92 (1H, br s, OH), 4.61 (1H, sept, J 6.2 Hz), 
4.67 (2H, s), 6.89 (1H, d, J 8.3 Hz), 6.92 (1H, dt, J 0.9 Hz, J 7.4 Hz), 7.23 – 7.29 (2H, m) in 
agreement with that reported by Fukatsu et al. [61]; 13C NMR (125 MHz, CDCl3) δ 22.0, 
62.0, 70.0, 112.4, 120.3, 128.5, 128.6, 130.0, 155.6.  
4.6.3. General method for preparation of  2-aryl-1,3-thiazolidine methyl esters (11a-f) 
 
These compounds 11a-f were prepared using the general method described by Gududuru et 
al. [35].  
Thionyl chloride (8.3 mL, 110 mmol) was added dropwise under an atmosphere of argon to a 
solution of L-cysteine (8) (9.00 g, 74 mmol) in 150 mL MeOH. The reaction mixture was 
refluxed for 3 h then evaporated in vacuo, then co-evaporated with toluene (2 x 5 mL) to 
afford the hydrochloride salt of the methyl ester of L-cysteine (9) as white solid. One-sixth of 
this material (9) (12.4 mmol) was dissolved in water/ ethanol (1:1) (15 mL). Sodium 
hydrogen carbonate (1.14 g, 13.6 mmol) was added and, after 10 min, the aromatic aldehyde 
(10a-f) (12.38 mmol) was added and the reaction mixture was stirred for 14 h. The ethanol 
was evaporated in vacuo and the aqueous residue was extracted with DCM (50 mL). The 
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organic layer was washed with water (25 mL), dried over Na2SO4, filtered and evaporated in 
vacuo to afford the crude products 11a-f. 
4.6.3.1. (2R/2S, 4R)-Methyl 2-(p-tolyl)thiazolidine-4-carboxylate (11a) 
 
The crude product was purified by silica flash column chromatography (10% EtOAc in LP) to 
afford a mixture of cis and trans isomers of 11a as a yellow oil (1.90 g, 65%) Rf : 0.31 (20% 
EtOAc in LP, UV and Ce(SO4)2 dip). 1H NMR (300 MHz, CDCl3) δ 2.32 (s) and 2.34 (s) 
integrate for 3H, 2.72 (1H, br s, NH), 3.06 – 3.21 (1H, m), 3.32 – 3.52 (1H, m), 3.77 (s) and 
3.76 (s) integrate for 3H, 3.96 (0.6H, dd, J 7.1 Hz, J 8.9 Hz), 4.21 (0.4H, dd, J 5.7 Hz, J 7.1 
Hz), 5.52 (0.6H, s), 5.77 (0.4H, s), 7.11 – 7.17 (2H, m), 7.35 – 7.42 (2H, m); 13C NMR (75 
MHz, CDCl3) δ 20.8, 20.9, 37.8, 38.9, 52.16, 52.22, 64.1, 65.2, 70.5, 72.2,  126.6, 127.0, 
128.8, 129.0, 134.9, 137.3, 137.8, 138.2, 171.3, 171.9 in agreement with that described by 
Paul and Korytnyk [62]. 
4.6.3.2. (2R/2S, 4R)-Methyl 2-phenylthiazolidine-4-carboxylate (11b) [35] 
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The crude product was purified by silica flash column chromatography (10% EtOAc in LP) to 
afford cis and trans mixture of 11b as a yellow oil (2.055 g, 74%) Rf : 0.31 (20% EtOAc in 
LP, UV and Ce(SO4)2 dip). 1H NMR (300 MHz, CDCl3) δ 2.65 (1H, br s, NH), 3.11 (1H, dd, 
J 9.0 Hz, J 10.2 Hz), 3.20 (0.5H, dd, J 6.0 Hz, J 10.8 Hz), 3.38 (0.5H, t, J 10.5 Hz), 3.41 – 
3.49 (1H, m), 3.79 (1.5H, s), 3.80 (3H, s), 3.99 (1H, dd, J 7.2 Hz, J 9.0 Hz), 4.21 (0.5H, dd, J 
6.0 Hz, J 6.9 Hz), 5.56 (1H, s), 5.82 (0.5H, s), 7.23 – 7.40 (5H, m), 7.47 – 7.52 (3H, m) in 
agreement with that described by Gududuru et al. [35]; 13C NMR (75 MHz, CDCl3) δ 38.0, 
39.1, 52.4, 52.5, 64.2, 65.4, 70.7, 72.5,  126.8, 127.3, 127.8, 128.3, 128.57, 128.60, 138.1, 
141.0, 171.5, 172.1. 
4.6.3.3. (2R/2S, 4R)-Methyl 2-(4-methoxyphenyl)thiazolidine-4-carboxylate (11c) 
 
The crude product was purified by silica flash column chromatography (10-60% EtOAc in 
LP) to afford cis and trans mixture of 11c as a yellow oil (2.525 g, 81%) Rf : 0.19 (20% 
EtOAc in LP, UV and Ce(SO4)2 dip). ESI – MS, m/z: 276 [M + Na]+. HRMS calculated for 
C12H15NNaO3S+ 276.0665, found 296.0654. 1H NMR (500 MHz, CDCl3) δ 3.08 (dd, J 8.9 
Hz, J 10.3 Hz) and 3.20 (dd, J 5.5 Hz, J 10.7 Hz) integrate for 1H, 3.36 (dd, J 7.1 Hz, J 10.7 
Hz) and 3.43 (dd, J 7.1 Hz, J 10.3 Hz) integrate for 1H, 3.766 (s), 3.770 (s), 3.78 (s) and 3.79 
(s) integrate for 6H (2 x CH3), 3.95 (0.7H, dd, J 7.2 Hz, J 9.0), 4.21 (0.3H, dd, J 5.5 Hz, J 7.2 
Hz), 5.50 (s) and 5.74 (s) integrate for 1H, 6.83 – 6.88 (2H, m), 7.38 – 7.44 (2H, m); 13C 
NMR (125 MHz, CDCl3) δ 38.0, 39.2, 52.5, 52.6, 55.27, 55.29, 64.2, 65.4, 70.6, 72.3, 113.7, 
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114.0, 128.2, 128.7, 130.1, 132.9, 159.3, 159.8, 171.6, 172.3. NMR spectra are in agreement 
with those reported by Anwar and Moloney [63]. 
4.6.3.4. (2R/2S, 4R)-Methyl 2-(4-chlorophenyl)thiazolidine-4-carboxylate (11d) 
 
The crude product was purified by silica flash column chromatography (10-50% EtOAc in 
LP) to afford cis and trans mixture of 11d as a yellow oil (1.80 g, 57%) Rf : 0.31 (20% EtOAc 
in LP, UV and Ce(SO4)2 dip). ESI – MS, m/z: 280 [M + Na]+. HRMS calculated for 
C11H12ClNNaO2S+ 280.0169, found 280.0171. 1H NMR (300 MHz, CDCl3) δ 2.68 (1H, br s, 
NH), 3.06 – 3.18 (1H, m), 3.35 (dd, J 7.1 Hz, J 10.6 Hz) and 3.44 (dd, J 7.1 Hz, J 10.3 Hz) 
integrate for 1H, 3.78 (s) and 3.79 (s) integrate for 3H, 3.96 (0.6H, dd, J 7.1 Hz, J 8.9), 4.13 
(0.4H, t, J 6.5 Hz), 5.54 (s) and 5.77 (s) integrate for 1H, 7.26 – 7.34 (2H, m), 7.40 – 7.47 
(2H, m); 13C NMR (75 MHz, CDCl3) δ 38.0, 39.1, 52.48, 52.52, 64.0, 65.4, 69.8, 71.7, 128.2, 
128.4, 128.7, 128.8, 133.4, 134.3, 136.7, 139.9, 171.4, 172.0. 
4.6.3.5. (2R/2S, 4R)-Methyl 2-(2-chlorophenyl)thiazolidine-4-carboxylate (11e) 
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The crude product was purified by silica flash column chromatography (10-50% EtOAc in 
LP) to afford cis and trans mixture of 11e as a yellow oil (2.50 g, 79%) Rf : 0.37 (20% EtOAc 
in LP, UV and Ce(SO4)2 dip ESI – MS, m/z: 280 [M + Na]+. HRMS calculated for 
C11H12ClNNaO2S+ 280.0169, found 280.0174. 1H NMR (300 MHz, CDCl3) δ 2.88 (1H, t, J 
10.4 Hz, NH), 3.03 – 3.14  (1H, m), 3.33 (dd, J 6.5 Hz, J 10.6 Hz) and 3.46 (dd, J 6.9 Hz, J 
10.2 Hz) integrate for 1H, 3.80 (s) and 3.81 (s) integrate for 3H, 3.99 (dd, J 4.0 Hz, J 6.9) and 
4.25 (t, J 6.7 Hz) integrate for 1H, 5.94 (s) and 6.08 (s) integrate for 1H, 7.15 – 7.40 (4H, m), 
7.57 (dd, J 1.7 Hz, J 7.6 Hz) and 7.71 (dd, J 2.1 Hz, J 7.5 Hz) integrate for 1H; 13C NMR (75 
MHz, CDCl3) δ 37.4, 38.9, 52.5, 52.6, 65.4, 68.3, 126.5, 126.8, 127.3, 128.1, 128.5, 129.7, 
129.8, 132.9, 133.7, 135.8, 140.0, 171.5, 172.0.  
4.6.3.6. (2R/2S, 4R)-Methyl 2-(naphth-1-yl)thiazolidine-4-carboxylate (11f) 
 
The crude product was purified by recrystallisation from diethyl ether to afford cis and trans 
mixture of 11f as white needles (1.232 g, 37%) Rf : 0.33 (20% EtOAc in LP, UV and 
Ce(SO4)2 dip). ESI – MS, m/z: 296 [M + Na]+. HRMS calculated for C15H15NNaO2S+ 
296.0716, found 296.0724. 1H NMR (300 MHz, CDCl3) δ 2.85 (1H, br s, NH), 3.12 (dd, J 9.3 
Hz, J 10.2 Hz) and 3.20 (dd, J 6.3 Hz, J 10.5 Hz) integrate for 1H, 3.39 (dd, J 6.6 Hz, J 10.5 
Hz) and 3.51 (dd, J 7.2 Hz, J 10.5 Hz) integrate for 1H, 3.80 (s) and 3.82 (s) integrate for 3H, 
4.13 (dd, J 7.2 Hz, J 9.3 Hz) and 4.36 (t, J 6.5 Hz) integrate for 1H, 6.30 (s) and 6.49 (s) 
integrate for 1H, 7.40 – 7.58 (3H, m), 7.75 – 7.97 (3H, m), 8.13 (d, J 8.4) and 8.20 (d, J 8.4) 
integrate for 1H; 13C NMR (75 MHz, CDCl3) δ 37.9, 38.7, 52.6, 64.7, 65.6, 67.9, 69.3, 122.5, 
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123.5, 123.6, 123.8, 125.2, 125.3, 125.8, 125.9, 126.3, 126.5, 128.5, 128.7, 128.8, 129.2, 
130.8, 131.4, 133.6, 133.7, 133.9, 136.6, 171.6, 172.3. 
4.6.4. General method for preparation of 2-aryl-1,3-thiazole methyl esters (12a-f) 
 
These compounds 12a-f were prepared using the general method described by Gududuru et 
al. [35]. NBS (2.1 eq, 835 mg, 4.69 mmol) and benzoyl peroxide (0.03 eq, 16.2 mg, 0.067 
mmol) were added to a solution of 11a-f (2.233 mmol) in CCl4 (25 mL). The reaction mixture 
was refluxed for 14 h. The hot mixture was filtered and evaporated in vacuo. The crude 
product was purified by silica flash column chromatography to afford the corresponding 
thiazole derivatives 12a-f.  
4.6.4.1. Methyl 2-p-tolylthiazole-4-carboxylate (12a) 
 
The crude product was purified by silica flash column chromatography (0-10% EtOAc in LP) 
to afford 12a as yellow solid (120 mg, 23%) Rf : 0.23 (10% EtOAc in LP, UV). ESI – MS, 
m/z: 256 [M + Na]+. HRMS calculated for C12H11NNaO2S+ 256.0403, found 256.0404. 1H 
NMR (300 MHz, CDCl3) δ 2.35 (3H, s), 3.93 (3H, s), 7.19 (2H, d, J 8.0 Hz), 7.84 (2H, d, J 
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8.1 Hz), 8.10 (1H, s); 13C NMR (75 MHz, CDCl3) δ 21.4, 52.4, 126.8, 126.9, 129.6, 130.0, 
141.0, 147.4, 161.9, 169.1. NMR spectra are in agreement with those reported by Wang et al. 
[64]. 
4.6.4.2. Methyl 2-phenylthiazole-4-carboxylate (12b) 
  
The crude product was purified by silica flash column chromatography (0-10% EtOAc in LP) 
to afford 12b as a yellow solid (139 mg, 26%) Rf : 0.23 (10% EtOAc in LP, UV and KMnO4 
dip). 1H NMR (300 MHz, CDCl3) δ 3.93 (3H, s), 7.39 – 7.41 (3H, m), 7.93 – 7.97 (2H, m), 
8.12 (1H, s) in agreement with that described by Dawsey et al. [65]; 13C NMR (75 MHz, 
CDCl3) δ 52.3, 126.8, 127.2, 128.9, 130.6, 132.6, 147.6, 161.8, 168.9. 
4.6.4.3. Methyl 2-(4-methoxyphenyl)thiazole-4-carboxylate (12c) 
 
The crude product was purified by silica flash column chromatography (0-60% EtOAc in LP) 
to afford 12c as yellow solid (93 mg, 17%) Rf : 0.39 (20% EtOAc in LP, UV). ESI – MS, m/z: 
272 [M + Na]+. HRMS calculated for C12H11NNaO3S+ 272.0352, found 272.0352. 1H NMR 
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(300 MHz, CDCl3) δ 3.82 (3H, s), 3.93 (3H, s), 6.92 (2H, d, J 8.9 Hz), 7.89 (2H, d, J 8.9 Hz), 
8.07 (1H, s); 13C NMR (75 MHz, CDCl3) δ 52.4, 55.4, 114.2, 126.5, 128.5, 131.7, 147.4, 
161.6, 162.0, 168.8. NMR spectra are in agreement with those reported by Dawsey et al. [65]. 
4.6.4.4. Methyl 2-(4-chlorophenyl)thiazole-4-carboxylate (12d) 
 
The crude product was purified by silica flash column chromatography (0-10% EtOAc in LP) 
to afford 12d as yellow solid (108 mg, 19%) Rf : 0.48 (20% EtOAc in LP, UV and KMnO4 
dip). ESI – MS, m/z: 276 [M + Na]+. HRMS calculated for C11H8ClNNaO2S+ 275.9856, 
found 275.9860. 1H NMR (300 MHz, CDCl3) δ 3.93 (3H, s), 7.37 (2H, d, J 8.4 Hz), 7.88 (2H, 
d, J 8.5 Hz), 8.13 (1H, s); 13C NMR (75 MHz, CDCl3) δ 52.4, 127.4, 128.1, 129.2, 131.1, 
136.7, 147.7, 161.7, 167.5. 
4.6.4.5. Methyl 2-(2-chlorophenyl)thiazole-4-carboxylate (12e) 
 
The crude product was purified by silica flash column chromatography (0-10% EtOAc in LP) 
to afford 12e as yellow solid (181 mg, 32%) Rf : 0.48 (20% EtOAc in LP, UV and KMnO4 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
32 
 
dip). ESI – MS, m/z: 276 [M + Na]+. HRMS calculated for C11H8ClNNaO2S+ 275.9856, 
found 275.9859. 1H NMR (300 MHz, CDCl3) δ 3.90 (3H, s), 7.27 – 7.32 (2H, m), 7.39 – 7.42 
(1H, m), 8.18 – 8.22 (1H, m), 8.23 (1H, s); 13C NMR (75 MHz, CDCl3) δ 52.3, 127.0, 128.6, 
130.3, 130.8, 130.9, 131.2, 131.8, 146.1, 161.7, 164.0 
4.6.4.6. Methyl 2-(naphth-1-yl)thiazole-4-carboxylate (12f) 
 
The crude product was purified by silica flash column chromatography (0-10% EtOAc in LP) 
to afford 12f as viscous yellow oil (95 mg, 16%) Rf : 0.42 (20% EtOAc in LP, UV and 
KMnO4 dip). ESI – MS, m/z: 292 [M + Na]+. HRMS calculated for C15H11NNaO2S+ 
292.0403, found 292.0410. 1H NMR (300 MHz, CDCl3) δ 3.98 (3H, s), 7.47 – 7.63 (3H, m), 
7.78 (1H, dd, J 1.2 Hz, J 7.2 Hz), 7.87 – 7.96 (2H, m), 8.30 (1H, s), 8.65 – 8.69 (1H, m); 13C 
NMR (75 MHz, CDCl3) δ 52.4, 124.9, 125.5, 126.5, 127.7, 128.2, 128.3, 128.8, 130.0, 130.5, 
131.0, 133.8, 147.5, 162.0, 168.1. NMR spectra are in agreement with those reported by Liu 
et al. [66]. 
4.6.5. General method for preparation of 2-aryl-1,3-thiazole-4-carboxylic acids (4a-f) 
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These compounds 4a-f were prepared using the general method described by Gududuru et al. 
[35]. Sodium hydroxide solution (1M, 2.5 mL) was added to a solution of (12a-f), 40-175 mg, 
in methanol (2.5 mL) at 0 oC. The solution was stirred for 2 h, and then the methanol was 
evaporated in vacuo. The solution was acidified with conc HCl and extracted with EtOAc (3 x 
50 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), 
then dried over Na2SO4, filtered and evaporated in vacuo to afford the corresponding 
carboxylic acid derivatives 4a-f. 
 
 
 
 
4.6.5.1. 2-(p-Tolyl)thiazole-4-carboxylic acid (4a) 
 
4a was obtained as a white solid (39 mg, 98%) Rf : 0.12 (30% EtOAc in LP and 2 drops 
AcOH, UV and KMnO4 dip). 1H NMR (400 MHz, MeOD) δ 2.36 (3H, s), 7.26 (2H, d, J 7.6 
Hz), 7.84 (2H, d, J 8.0 Hz), 8.27 (1H, s)  in agreement with that reported by Aliabadi et al. 
[67]; 13C NMR (100 MHz, MeOD) δ 21.4, 127.8, 128.5, 130.8, 131.4, 142.6, 149.2, 164.2, 
170.6.  
4.6.5.2. 2-Phenylthiazole-4-carboxylic acid (4b) 
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4b was obtained as a white solid (77 mg, 80%) Rf : 0.10 (30% EtOAc in LP and 2 drops 
AcOH, UV and KMnO4 dip). 1H NMR (300 MHz, MeOD) δ 7.44 – 7.46 (3H, m), 7.95 – 7.98 
(2H, m), 8.31 (1H, s) in agreement with that described by Zhao et al. [68]; 13C NMR (75 
MHz, MeOD) δ 127.8, 129.0, 130.2, 131.9, 134.0, 149.3, 164.1, 170.4. 
 
 
 
4.6.5.3. 2-(4-Methoxyphenyl)thiazole-4-carboxylic acid (4c) [69] 
 
4c was obtained as a yellow solid (58 mg, 84%). 1H NMR (400 MHz, DMSO-d6) δ 3.82 (3H, 
s), 7.06 (2H, d, J 8.9 Hz), 7.90 (2H, d, J 8.9 Hz), 8.40 (1H, s); 13C NMR (100 MHz, DMSO-
d6) δ 55.4, 114.6, 127.8, 128.0, 130.4, 147.8, 161.2, 162.0, 167.3. 
4.6.5.4. 2-(4-Chlorophenyl)thiazole-4-carboxylic acid (4d) 
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4d was obtained as a white solid (101 mg, 100%). 1H NMR (400 MHz, DMSO-d6) δ 7.58 
(2H, d, J 8.5 Hz), 7.98 (2H, d, J 8.5 Hz), 8.51 (1H, s); 13C NMR (100 MHz, DMSO-d6) δ 
128.1, 129.2, 129.4, 131.3, 135.3, 148.2, 161.9, 166.1. NMR spectra are in agreement with 
those reported by Ma et al. [70]. 
 
 
 
4.6.5.5. 2-(2-Chlorophenyl)thiazole-4-carboxylic acid (4e) 
 
4e was obtained as a white solid (165 mg, 100%). 1H NMR (400 MHz, DMSO-d6) δ 7.50 – 
7.57 (2H, m), 7.64 – 7.68 (1H, m), 8.16 – 8.20 (1H, m), 8.63 (1H, s) in agreement with that 
described by Carpenter et al. [71]; 13C NMR (100 MHz, DMSO-d6) δ 127.9, 130.1, 130.7, 
130.89, 130.90, 131.7, 147.0, 162.0, 162.7, 162.9. 
4.6.5.6. 2-(Naphth-1-yl)thiazole-4-carboxylic acid (4f) 
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4f was obtained as a white solid (88 mg, 100%). 1H NMR (400 MHz, DMSO-d6) δ 7.60 – 
7.68 (3H, m), 7.94 (1H, dd, J 1.2 Hz, J 7.2 Hz), 8.04 (1H, dd, J 1.7 Hz, J 7.7 Hz), 8.11 (1H, d, 
J 8.4 Hz), 8.63 (1H, s), 8.83 (1H, dd, J 0.9 Hz, J 8.1 Hz) in agreement with that described by 
Carpenter et al. [71]; 13C NMR (100 MHz, DMSO-d6) δ 125.3, 125.4, 126.7, 127.7, 128.5, 
128.9, 129.3, 129.45, 129.47, 131.0, 133.6, 148.1, 162.2, 166.9. 
4.6.6. Synthesis of ethyl 2-(2-formylphenoxy)acetate (13) [36] 
 
Salicylaldehyde (5) (2.50 g, 2.18 mL, 21 mmol) was added to a suspension of potassium 
carbonate (3.06 g, 22 mmol) in acetone (75 mL). The mixture was stirred for 5 min at room 
temperature under an argon atmosphere. Ethyl 2-bromoacetate (3.75 g, 2.49 mL, 23 mmol) 
was added to the reaction mixture and the mixture was refluxed for 4 h. After cooling, the 
reaction mixture was filtered and the residue was washed with acetone. The filtrate was 
evaporated in vacuo and the residue was dried under high vacuum to remove any traces of 
salicylaldehyde to give compound 13 (3.66 g, 86%) Rf : 0.21 (10% EtOAc in LP, UV and 
KMnO4 dip). 1H NMR (300 MHz, CDCl3) δ 1.25 (3H, t, J 7.2 Hz), 4.23 (2H, q, J 7.1 Hz), 
4.72 (2H, s), 6.83 (1H, d, J 8.4 Hz), 7.01 – 7.07 (1H, m), 7.46 – 7.52 (1H, m), 7.82 (1H, dd, J 
1.8 Hz, J 7.7 Hz), 10.53 (1H, s); 13C NMR (75 MHz, CDCl3) δ 14.0, 61.5, 65.6, 112.6, 121.8, 
125.4, 128.5, 135.7, 160.1, 168.1, 189.5. 
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4.6.7. Synthesis of ethyl 2-(1-formylnaphth-2-yloxy)acetate (15)  
 
2-Hydroxynaphthaldehyde (14) (5.17 g, 30 mmol) was added to a suspension of potassium 
carbonate (4.56 g, 33 mmol) in acetone (115 mL). The mixture was stirred for 5 min at room 
temperature under an argon atmosphere. Ethyl 2-bromoacetate (5.51 g, 3.66 mL, 33 mmol) 
was added to the reaction mixture and the mixture was refluxed for 4 h. After cooling, the 
reaction mixture was filtered and the residue was washed with acetone. The filtrate was 
evaporated in vacuo to give the crude product as a light brown solid. The crude product was 
recrystallised from ethanol to give compound 15 as beige solid (3.72 g, 48%) Rf : 0.19 (10% 
EtOAc in LP, UV and KMnO4 dip). ESI – MS, m/z: 281 [M + Na]+. HRMS calculated for 
C15H14NaO4+ 281.0784, found 281.0789. 1H NMR (300 MHz, CDCl3) δ 1.27 (3H, t, J 7.1 Hz), 
4.26 (2H, q, J 7.1 Hz), 4.85 (2H, s), 7.10 (1H, d, J 9.1 Hz), 7.39 – 7.45 (1H, m), 7.58 – 7.64 
(1H, m), 7.75 (1H, dt, J 0.7 Hz, J 1.3 Hz, J 8.1 Hz), 8.01 (1H, d, J 9.1 Hz), 9.24 – 9.28 (1H, 
m) in agreement with that described by Yeap et al. [72]; 13C NMR (75 MHz, CDCl3) δ 14.1, 
61.7, 66.4, 113.2, 117.7, 125.14, 125.19, 128.2, 129.1, 129.9, 131.4, 137.3, 162.0, 168.2, 
192.1. 
4.6.8. Synthesis of  (2R/2S, 4R)-methyl 2-(2-(2-ethoxy-2-oxoethoxy)phenyl)thiazolidine-4-
carboxylate (11g) 
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L-Cysteine (9) was dissolved in ethanol:water (1:1) (15 mL). Sodium bicarbonate (1.14 g, 
13.61 mmol) was added, and after 10 min, the aromatic aldehyde 13 (2.58 g, 12.38 mmol) 
was added and stirred for 14 h. Ethanol was evaporated in vacuo and DCM (50 mL) was 
added and washed with water (25 mL), dried over Na2SO4, filtered and evaporated in vacuo to 
afford the crude product of 11g. The crude product was purified by silica flash column 
chromatography (10-60% EtOAc in LP) to afford cis and trans mixture of 11g as a brown 
solid (484 mg, 12%) Rf : 0.28 (30% EtOAc in LP, UV and KMnO4 dip). ESI – MS, m/z: 348 
[M + Na]+. HRMS calculated for C15H19NNaO5S+ 348.0876, found 348.0881. 1H NMR (400 
MHz, CDCl3) δ 1.12 – 1.20  (3H, m), 2.99 – 3.07 (1H, m), 3.21 – 3.34 (1H, m), 3.67 – 3.68 
(3H, m), 3.85 (0.5H, t, J 15.6 Hz), 4.10 – 4.17 (2H, m), 4.23 – 4.26 (0.5H, m), 4.55 – 4.57 
(2H, m), 5.78 (0.5H, s), 5.94 (0.5H, s), 6.68 (1H, dd, J 8.3 Hz, J 18.2 Hz), 6.83 – 6.92 (1H, 
m), 7.08 – 7.18 (1H, m), 7.33 (0.5H, d, J 7.6 Hz), 7.39 (0.5H, d, J 7.6 Hz); 13C NMR (100 
MHz, CDCl3) δ 13.76, 13.78, 37.3, 38.4, 52.01, 52.04, 60.9, 64.8, 65.3, 65.4, 65.6, 66.5, 67.4, 
111.7, 112.0, 121.2, 121.5, 126.6, 126.7, 128.1, 128.4, 129.3, 129.8, 154.9, 155.3, 168.0, 
168.2, 171.1, 171.8. 
4.6.9. Synthesis of (2R/2S, 4R)-methyl 2-(2-(2-ethoxy-2-oxoethoxy)naphth-1-
yl)thiazolidine-4-carboxylate (11h) 
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L-Cysteine (9) was dissolved in ethanol : water (1:1) (15 mL). Sodium bicarbonate (1.32 g, 
15.69 mmol) was added, and after 10 min, the aromatic aldehyde 15 (3.68 g, 14.26 mmol) 
was added to form a white precipitate immediately. The reaction mixture was filtered using 
ethanol : water (1:1). The residue was taken up with DCM (100 mL) and washed with water 
(25 mL), dried over Na2SO4, filtered and evaporated in vacuo to afford the crude product of 
11h. The crude product was purified by suspending it in ether (100 mL), filter and the residue 
was washed thoroughly with ether to afford a mixture of cis and trans 11h as a white solid 
(4.12 g, 77%) Rf : 0.29 (30% EtOAc in LP, UV and KMnO4 dip). ESI – MS, m/z: 398 [M + 
Na]+. HRMS calculated for C19H21NNaO5S+ 398.1033, found 398.1043. 1H NMR (500 MHz, 
CDCl3) δ 1.26 – 1.32 (3H, m), 3.27 (1H, t, J 10.0 Hz), 3.51 – 3.55 (1H, m), 3.59 (0.4H, dd, J 
2.0 Hz, J 10.5 Hz), 3.81 (s) and 3.82 (s) integrate for (3H), 4.01 – 4.04 (0.6H, m), 4.25 – 4.29 
(2H, m), 4.72 – 4.85 (2H, m), 6.53 (s) and 6.59 (s) integrate for (1H), 7.13 (1H, dd, J 9.0 Hz, 
J 16.5 Hz), 7.37 – 7.39 (1H, m), 7.49 – 7.53 (1H, m), 7.75 – 7.81 (2H, m), 8.10 (1H, dd, J 3.0 
Hz, J 8.5 Hz); 13C NMR (125 MHz, CDCl3) δ 14.15,  14.18, 38.5, 39.2, 52.41, 52.43, 61.5, 
61.6, 65.6, 66.0, 66.2, 66.6, 66.8, 66.9, 114.7, 114.9, 118.7, 119.1, 122.6, 122.9, 124.3, 124.4, 
127.3, 127.4, 128.5, 128.8, 129.8, 130.5, 130.7, 132.3, 132.5, 154.1, 154.3, 168.3, 168.6, 
171.3, 172.7. 
4.6.10. Synthesis of methyl 2-(2-(2-ethoxy-2-oxoethoxy)phenyl)thiazole-4-carboxylate 
(12g) 
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This compound 12g was prepared using the general method described by Gududuru et al. 
[35]. NBS (2.1 eq, 556 mg, 3.12 mmol) and benzoyl peroxide (0.03 eq, 11 mg, 0.045 mmol) 
were added to a solution of 11g (483 mg, 1.49 mmol) in CCl4 (15 mL). The reaction mixture 
was refluxed for 14 h. The hot mixture was filtered and evaporated in vacuo. The crude 
product was purified by silica flash column chromatography (10-60% EtOAc in LP) to afford 
the corresponding thiazole derivative 12g as a brown solid (80 mg, 17%) Rf : 0.37 (30% 
EtOAc in LP, UV and KMnO4 dip). ESI – MS, m/z: 344 [M + Na]+. HRMS calculated for 
C15H15NNaO5S+ 344.0563, found 344.0565. 1H NMR (400 MHz, CDCl3) δ 1.24 (3H, t, J 7.1 
Hz), 3.92 (3H, s), 4.24 (2H, q, J 7.1 Hz), 4.78 (2H, s), 6.86 (1H, dd, J 0.9 Hz, J 8.5 Hz), 7.06 
– 7.10 (1H, m), 7.31 – 7.35 (1H, m), 8.20 (1H, s), 8.47 (1H, dd, J 1.7 Hz, J 7.9 Hz); 13C NMR 
(100 MHz, CDCl3) δ 14.0, 52.2, 61.5, 65.6, 111.8, 121.9, 122.0, 128.5, 129.4, 131.2, 145.6, 
154.6, 162.2, 162.8, 167.8. 
 
 
 
4.6.11. Synthesis of methyl 2-(2-(2-ethoxy-2-oxoethoxy)naphth-1-yl)thiazole-4-
carboxylate (12h) 
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This compound 12h was prepared using the general method described by Gududuru et al. 
[35]. NBS (2.1 eq, 2.78 g, 15.60 mmol) and benzoyl peroxide (0.03 eq, 55 mg, 0.23 mmol) 
were added to a solution of 11h (2.81 g, 7.50 mmol) in CCl4 (75 mL) and the reaction mixture 
was refluxed for 14 h. The hot mixture was filtered and evaporated in vacuo. The crude 
product was purified by silica flash column chromatography (10-60% EtOAc in LP) to afford 
the corresponding thiazole derivative 12h as a brown solid (211 mg, 8%) Rf : 0.34 (30% 
EtOAc in LP, UV and KMnO4 dip). ESI – MS, m/z: 394 [M + Na]+. HRMS calculated for 
C19H17NNaO5S+ 394.0720, found 394.0727.1H NMR (300 MHz, CDCl3) δ 1.19 (3H, t, J 7.1 
Hz), 3.92 (3H, s), 4.16 (2H, q, J 7.1 Hz), 4.68 (2H, s), 7.14 (1H, d, J 9.1 Hz), 7.31 – 7.37 (1H, 
m), 7.40 – 7.47 (1H, m), 7.74 (1H, d, J 8.7 Hz), 7.86 (1H, d, J 9.0 Hz), 7.96 (1H, d, J 8.6 Hz), 
8.40 (1H, s); 13C NMR (75 MHz, CDCl3) δ 13.9, 52.2, 61.2, 66.3, 113.2, 116.5, 124.5, 124.7, 
127.8, 129.2, 129.4, 132.1, 132.9, 146.3, 153.7, 162.0, 162.9, 168.3. 
4.6.12. Synthesis of 2-(2-(carboxymethoxy)phenyl)thiazole-4-carboxylic acid (4g) 
 
This compound 4g was prepared using the general method described by Gududuru et al. [35]. 
Sodium hydroxide solution (1 M, 3 mL) was added to a solution of the thiazole methyl ester 
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derivative 12g (80 mg, 0.25 mmol) in methanol (6 mL). The solution was stirred for 4 h, and 
then methanol was evaporated in vacuo. The solution was acidified with conc HCl and 
extracted with EtOAc (3 x 50 mL). The combined organic layer was washed with brine (50 
mL), water (50 mL), dried over Na2SO4, and evaporated in vacuo to afford the corresponding 
carboxylic acid derivative 4g as a brown solid (51 mg, 73%). ESI – MS, m/z: 300 [M + Na - 
2H]-. HRMS calculated for C12H7NNaO5S- 299.9948, found 299.9956. 1H NMR (500 MHz, 
DMSO) δ 4.99 (2H, s), 7.15 (2H, dd, J 8.9 Hz, J 17.6Hz), 7.45 (1H, dt, J 1.7 Hz, J 8.7 Hz, J 
9.7 Hz), 8.29 (1H, dd, J 1.7 Hz, J 7.9 Hz), 8.51 (1H, s); 13C NMR (125 MHz, DMSO) δ 65.1, 
113.0, 121.2, 121.5, 128.0, 129.5, 131.5, 146.2, 154.8, 161.7, 162.4, 169.6. 
4.6.13. Synthesis of 2-(2-(carboxymethoxy)naphth-1-yl)thiazole-4-carboxylic acid (4h) 
 
4h was prepared using the general method described by Gududuru et al. [35]. Sodium 
hydroxide solution (1 M, 6 mL) was added to a solution of the thiazole methyl ester derivative 
12h (143 mg, 0.39 mmol) in methanol (6 mL). The solution was stirred for 4 h, and then 
methanol evaporated in vacuo. The solution was acidified with conc HCl and extracted with 
EtOAc (3 x 50 mL). The combined organic layers were washed with brine (50 mL) and water 
(50 mL), the dried over Na2SO4, filtered and evaporated in vacuo to afford the corresponding 
carboxylic acid derivative 4h as a yellow solid (101 mg, 80%). ESI – MS, m/z: 350 [M + Na - 
2H]-. HRMS calculated for C16H9NNaO5S- 350.0105, found 350.0102. 1H NMR (500 MHz, 
DMSO) δ 4.97 (2H, s), 7.42 – 7.45 (1H, m), 7.48 – 7.53 (2H, m), 7.94 (1H, d, J 7.6 Hz), 8.07 
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– 8.10 (2H, m), 8.68 (1H, s); 13C NMR (125 MHz, DMSO) δ 65.2, 113.9, 115.0, 124.3, 124.4, 
127.9, 128.2, 128.7, 130.4, 132.1, 146.8, 154.0, 162.0, 162.4, 170.0. 
4.6.14. General method for preparation of 2-aryl-1,3-thiazolidine-4-carboxylic acids 
(16a-c and 16f-j) 
 
16a-c and 16f-j were prepared using the general method described by Gududuru et al. [35]. A 
mixture of L-cysteine (8) (0.5 g, 4.12 mmol) and appropriate aryl aldehyde (10a-c and 10f-j) 
(4.12 mmol) in ethanol (15 mL) was stirred at room temperature for 5 h, and the solid 
separated was collected by filtration, washed with diethyl ether and dried to afford 16a-c and 
16f-j.  
4.6.14.1. (2R/2S, 4R)-2-(p-tolyl)thiazolidine-4-carboxylic acid (16a) [35]  
 
16a was obtained as a white solid (582 mg, 63%). 1H NMR (400 MHz, DMSO-d6) δ 2.27 (s) 
and 2.29 (s) integrate for 3H, 2.79 (0.3H, dd, J 6.5 Hz, J 14.0 Hz), 2.89 (0.4H, dd, J 4.2 Hz, J 
14.0 Hz), 3.05 (0.6H, dd, J 8.7 Hz, J 10.0 Hz), 3.12 (0.7H, dd, J 4.5 Hz, J 10.3 Hz), 3.27 
(0.7H, dd, J 7.2 Hz, J 10.2 Hz), 3.35 (0.7H, dd, J 7.2 Hz, J 10.1 Hz), 3.44 (0.4H, dd, J 4.2 Hz, 
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J 6.4 Hz), 3.85 (0.6H, dd, J 7.1 Hz, J 8.6 Hz), 4.21 (0.6H, dd, J 4.5 Hz, J 7.1 Hz), 5.45 (0.5H, 
s), 5.62 (0.6H, s), 7.12 (1H, d, J 7.8 Hz), 7.16 (1H, d, J 7.8 Hz), 7.30 (1H, d, J 8.1 Hz), 7.37 
(1H, d, J 8.1 Hz) in agreement with that described by [35]; 13C NMR (100 MHz, DMSO-d6) δ 
20.6, 20.7, 37.9, 38.5, 64.9, 65.5, 71.0, 71.7, 126.8, 127.1, 128.7, 129.0, 135.9, 136.7, 137.6, 
138.1, 172.3, 173.0. 
4.6.14.2. (2R/2S, 4R)-2-phenylthiazolidine-4-carboxylic acid (16b) [35]  
 
16b was obtained as a white solid (570 mg, 66%). 1H NMR (400 MHz, DMSO-d6) δ 3.05 – 
3.14 (1H, m), 3.27 – 3.39 (1H, m), 3.87 – 3.91 (0.4H, m), 4.21 (0.5H, m), 5.49 (0.4H, s), 5.67 
(0.5H, s), 7.26 – 7.51 (5H, m) in agreement with that described in the literature [35]; 13C 
NMR (100 MHz, DMSO-d6) δ 38.0, 38.5, 64.9, 65.5, 71.0, 71.8, 126.9, 127.2, 127.5, 128.18, 
128.24, 128.4, 138.9, 141.3, 172.3, 172.9. 
4.6.14.3. (2R/2S, 4R)-2-(4-methoxyphenyl)thiazolidine-4-carboxylic acid (16c) [35]  
 
16c was obtained as a white solid (516 mg, 52%). 1H NMR (400 MHz, DMSO-d6) δ 2.79 
(0.6H, dd, J 6.5 Hz, J 14.0 Hz), 2.89 (0.6H, dd, J 4.2 Hz, J 14.0 Hz), 3.04 (0.8H, dd, J 8.7 Hz, 
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J 10.0 Hz), 3.13 (0.8H, dd, J 4.2 Hz, J 10.3 Hz), 3.27 (1H, dd, J 7.2 Hz, J 10.2 Hz), 3.35 (1H, 
dd, J 7.2 Hz, J 10.1 Hz), 3.43 (1H, dd, J 4.1 Hz, J 6.4 Hz), 3.73 (s) and 3.74 (s) integrate for 
3H, 3.84 (0.8H, dd, J 7.2 Hz, J 8.7 Hz), 4.22 (0.7H, dd, J 4.2 Hz, J 7.1 Hz), 5.44 (0.5H, s), 
5.59 (0.5H, s), 6.87 (1H, d, J 8.7 Hz), 6.91 (1H, d, J 8.7 Hz), 7.35 (1H, d, J 8.7 Hz), 7.42 (1H, 
d, J 8.7 Hz) in agreement with that described in the literature [35]; 13C NMR (100 MHz, 
DMSO-d6) δ 37.9, 38.6, 55.09, 55.14, 64.8, 65.5, 71.0, 71.6, 113.6, 113.8, 128.3, 128.6, 
130.7, 132.8, 158.7, 159.2, 172.3, 173.1. 
4.6.14.4. (2R/2S, 4R)-2-(naphth-1-yl)thiazolidine-4-carboxylic acid (16f)  
 
16f was obtained as a white solid (728 mg, 68%). 1H NMR (400 MHz, DMSO-d6) δ 2.82 
(0.7H, dd, J 6.4 Hz, J 14.0 Hz), 2.91 (0.8H, dd, J 4.0 Hz, J 14.0 Hz), 3.06 – 3.12 (2H, m), 
3.32 (2H, dd, J 6.8 Hz, J 10.0 Hz), 3.44 - 3.48 (2H, m), 4.07 (1H, dd, J 7.2 Hz, J 8.8 Hz), 4.26 
(1H, t, J 6.4 Hz), 6.27 (0.5H, s), 6.44 (1H, s), 7.47 – 7.61 (5H, m), 7.74 (1H, d, J 7.2 Hz), 7.84 
– 7.98 (4H, m), 8.08 (1H, d, J 8.4 Hz), 8.19 (0.5H, d, J 8.3 Hz); 13C NMR (100 MHz, DMSO-
d6) δ 37.8, 38.1, 55.8, 65.1, 65.4, 68.0, 68.3, 122.3, 123.3, 123.5, 123.6, 125.3, 125.5, 125.7, 
125.9, 126.1, 126.3, 127.7, 128.4, 128.6, 130.4, 130.7, 133.2, 133.3, 134.6, 137.2, 172.4, 
173.0. NMR spectra are in agreement with those reported by Schneider et al.  [73]. 
 
4.6.14.5. (2R/2S, 4R)-2-(2-hydroxynaphth-1-yl)thiazolidine-4-carboxylic acid (16g)  
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NHS
OH
O
16g
OH
 
16g was obtained as a yellow solid (793 mg, 70%). 1H NMR (500 MHz, DMSO-d6) δ 2.76 
(1H, dd, J 6.6 Hz, J 13.9 Hz), 2.87 (1H, dd, J 4.2 Hz, J 14.1 Hz), 3.11 (1H, t, J 9.2 Hz), 3.22 
(1H, dd, J 4.3 Hz, J 10.7 Hz), 3.36 (2H, dd, J 4.2 Hz, J 6.7 Hz), 3.40 - 3.44 (2H, m), 3.98 
(0.5H, t, J 7.6 Hz), 4.43 (0.3H, t, J 5.3 Hz), 6.34 (0.5H, s), 6.47 (0.3H, s), 7.03 (1H, dd, J 8.8 
Hz, J 39.2 Hz), 7.28 (1H, t, J 7.3 Hz), 7.45 (1H, t, J 7.6 Hz), 7.69 – 7.79 (2H, m), 7.91 (0.5H, 
d, J 8.6 Hz); 13C NMR (125 MHz, DMSO-d6) δ 26.3, 40.7, 56.4, 74.3, 120.1, 122.1, 127.2, 
168.4.  
4.6.14.6. (2R/2S, 4R)-2-(4-hydroxyphenyl)thiazolidine-4-carboxylic acid (16h)  
 
16h was obtained as a white solid (592 mg, 64%). 1H NMR (400 MHz, DMSO-d6) δ 2.82 
(0.3H, dd, J 6.4 Hz, J 14.1 Hz), 2.90 (0.3H, dd, J 4.2 Hz, J 14.1 Hz), 3.03 (0.6H, dd, J 8.7 Hz, 
J 10.0 Hz), 3.13 (0.6H, dd, J 4.0 Hz, J 10.2 Hz), 3.26 (0.6H, dd, J 7.3 Hz, J 10.3 Hz), 3.34 
(0.6H, dd, J 7.2 Hz, J 10.1 Hz), 3.50 (0.3H, dd, J 4.2 Hz, J 6.3 Hz), 3.81 (0.8H, dd, J 7.3 Hz, 
J 8.6 Hz), 4.23 (0.5H, dd, J 4.0 Hz, J 7.2 Hz), 5.39 (0.5H, s), 5.53 (0.5H, s), 6.69 (1H, d, J 8.6 
Hz), 6.73 (1H, d, J 8.5 Hz), 7.23 (1H, d, J 8.6 Hz), 7.29 (1H, d, J 8.5 Hz) in agreement with 
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that described by Song et al. [74]; 13C NMR (100 MHz, DMSO-d6) δ 37.8, 38.6, 64.8, 65.4, 
71.3, 71.9, 114.9, 115.2, 128.3, 128.5, 128.8, 130.8, 156.9, 157.4, 172.4, 173.2. 
4.6.14.7. (2R/2S, 4R)-2-(2-hydroxyphenyl)thiazolidine-4-carboxylic acid (16i)  
 
16i was obtained as a white solid (865 mg, 93%). 1H NMR (400 MHz, DMSO-d6) δ 2.96 
(1H, dd, J 9.1 Hz, J 9.9 Hz), 3.01 (1H, dd, J 5.3 Hz, J 10.2 Hz), 3.19 (1H, dd, J 6.8 Hz, J 10.1 
Hz), 3.33 (1H, dd, J 6.9 Hz, J 10.0 Hz), 3.82 (1H, dd, J 7.0 Hz, J 9.0 Hz), 4.20 (1H, dd, J 5.4 
Hz, J 6.6 Hz), 5.64 (1H, s), 5.83 (1H, s), 6.73 – 6.82 (4H, m), 7.03 – 7.07 (1H, m), 7.10 – 7.14 
(1H, m), 7.28 (1H, dd, J 1.6 Hz, J 7.5 Hz), 7.33 (1H, dd, J 1.6 Hz, J 7.6 Hz); 13C NMR (100 
MHz, DMSO-d6) δ 37.1, 38.2, 64.8, 65.2, 65.6, 67.7, 115.1, 115.7, 118.7, 119.0, 124.2, 
126.1, 127.6, 127.9, 128.1, 129.0, 154.6, 155.2, 172.5, 172.9. NMR spectra are in agreement 
with those reported by Jagtap et al. [75]. 
4.6.14.8. (2R/2S, 4R)-2-(furan-2-yl)thiazolidine-4-carboxylic acid (16j)  
 
16j was obtained as a very light brown solid (541 mg, 66%). 1H NMR (400 MHz, DMSO-d6) 
δ 2.96 – 3.00 (1.6H, m), 3.28 (1H, dd, J 6.8 Hz, J 10.1 Hz), 3.34 (0.6H, dd, J 7.0 Hz, J 10.0 
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Hz), 3.85 (0.7H, dd, J 7.0 Hz, J 8.9 Hz), 4.10 (1H, t, J 6.4 Hz), 5.59 (0.6H, s), 5.74 (1H, s), 
6.33 – 6.34 (1H, m), 6.37 (1H, dd, J 1.9 Hz, J 3.2 Hz), 6.43 (0.5H, dd, J 1.8 Hz, J 3.3 Hz), 
6.49 (0.5H, d, J 3.4 Hz), 7.57 (1H, dd, J 0.9 Hz, J 1.9 Hz), 7.64 (0.5H, dd, J 0.8 Hz, J 1.9 Hz); 
13C NMR (100 MHz, DMSO-d6) δ 37.8, 38.0, 63.9, 64.2, 64.7, 65.2, 106.3, 107.5, 110.3, 
110.6, 142.5, 142.9, 151.3, 154.4, 172.1, 172.5. NMR spectra are in agreement with those 
described by Braga et al. [76]. 
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• A lead inhibitor against Purple acid phosphatase has been further developed. 
• Compounds are active against both pig and red kidney bean Purple acid phosphatases. 
• A crystal structure of an inhibitor in complex with the red kidney bean enzyme (2.40 
Å) is reported. 
